SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL OMB Number: 3235-0104 Estimated average burden hours per response: 0.5

1. Name and Address of Reporting Person* Sims Karen (Last) (First) (Middle) C/O ARBUTUS BIOPHARMA CORPORATION 701 VETERANS CIRCLE (Street) WARMINSTER PA 18974 (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 07/10/2023	3. Issuer Name and Ticker or Trading Symbol Arbutus Biopharma Corp [ ABUS ]
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner X Officer (give title below) Other (specify below) Chief Medical Officer	5. If Amendment, Date of Original Filed (Month/Day/Year)
			6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Shares	28,900(1)	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	(2)	06/21/2027	Common Shares	15,000	3.55	D
Stock Option (Right to Buy)	(3)	04/16/2028	Common Shares	25,500	5.2	D
Stock Option (Right to Buy)	(4)	03/01/2029	Common Shares	28,000	4.57	D
Stock Option (Right to Buy)	(5)	02/17/2030	Common Shares	39,900	3.35	D
Stock Option (Right to Buy)	(6)	02/13/2031	Common Shares	39,900	4.33	D
Stock Option (Right to Buy)	(7)	01/20/2032	Common Shares	82,460	2.81	D
Stock Option (Right to Buy)	(8)	02/01/2033	Common Shares	57,800	2.9	D

Explanation of Responses:

1. Represents the grant of restricted stock units ("RSUs"), which represent a contingent right to receive one common share for each RSU. The RSUs vest in three equal annual installments beginning one year from the February 1, 2023 grant date, subject to the Reporting Person's continuous service as of each vesting date. Unless otherwise provided, on each vesting date, common shares will automatically be sold to satisfy the Reporting Person's tax withholding obligations in a non-discretionary transaction.

2. The option is fully vested as of June 21, 2020.

3. This option is fully vested as of April 16, 2021.

4. This option is fully vested as of March 1, 2022.

5. This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the February 17, 2020 grant date, subject to the Reporting Person's continuous service as of each vesting date.

6. This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the February 13, 2021 grant date, subject to the Reporting Person's continuous service as of each vesting date.

7. This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the January 20, 2022 grant date, subject to the Reporting Person's continuous service as of each vesting date.

8. This option vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the February 1, 2023 grant date, subject to the Reporting Person's continuous service as of each vesting date.

Remarks:

Exhibit 24: Power of Attorney

	/s/ David C. Hastings as attorney-in-fact for Karen Sims	07/12/2023
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.